Physician profile
Paul Stanton
NPI 1407841794
$6,332.41
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $301 · 2021: $967 · 2022: $1,798 · 2023: $2,415 · 2024: $41.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,889.36 | 2019-2024 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,307.70 | 2019-2024 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $680.18 | 2019-2023 | Entyvio, Gattex, Vpriv |
| Janssen Biotech, INC. | $326.80 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Ferring Pharmaceuticals INC. | $286.97 | 2019-2023 | Rebyota |
| Celgene Corporation | $246.04 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $174.39 | 2022-2023 | |
| Olympus America INC. | $172.89 | 2019-2021 | |
| Daiichi Sankyo INC. | $162.60 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $148.85 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $89.48 | 2022-2023 | Ibsrela |
| Pfizer INC. | $88.03 | 2019-2023 | |
| Qol Medical, LLC | $77.88 | 2019-2023 | Sucraid |
| Genzyme Corporation | $75.03 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $67.55 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.53 | 2021-2023 | Dificid |
| Medtronic, INC. | $59.21 | 2022 | |
| Braintree Laboratories, INC. | $52.01 | 2021-2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $50.70 | 2019-2020 | |
| Amgen INC. | $39.84 | 2022-2023 | Amjevita, Avsola |
| Mylan Institutional INC. | $36.81 | 2023 | Hulio |
| E.R. Squibb & Sons, L.L.C. | $34.80 | 2023 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.97 | 2023 | Cyltezo |
| Organon LLC | $32.00 | 2022-2023 | Hadlima |
| Ucb, INC. | $31.14 | 2019 | |
| Intercept Pharmaceuticals, INC. | $27.02 | 2023 | Ocaliva |
| Lilly USA, LLC | $26.08 | 2023 | |
| Alnylam Pharmaceuticals INC. | $20.92 | 2023 | Givlaari |
| Redhill Biopharma INC. | $16.25 | 2021 | |
| Allergan, INC. | $13.38 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,097.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.